title: Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
abstract: Tissue plasminogen activator was used to treat 228 children with 320 central venous catheter (CVC) occlusion events. Patency was restored in 91% of CVCs after 1 to 3 treatments, with no adverse events. Tissue plasminogen activator is effective in restoring patency to occluded CVCs and is a viable alternative to CVC removal or urokinase treatment.
authors.affiliation: Division of Critical Care Medicine, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Jacobs
authors.forename: M
authors.initials: M
authors.lastname: Haygood
authors.forename: J
authors.initials: J
authors.lastname: Hingl
mesh_terms: D000293:Adolescent; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017063:Outcome Assessment, Health Care; D011994:Recombinant Proteins / Q000627:therapeutic use*; D019233:Retreatment; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D017211:Treatment Failure; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator